Washington, D.C. 20549


FORM 12B-25






Check One:


  Form 10-K
  Form 20-F
  Form 11-K
  Form 10-Q
  Form 10-D
  Form N-SAR
  Form N-CSR


For Period Ended: December 31, 2016


  Transition Report on Form 10-K
  Transition Report on Form 20-F
  Transition Report on Form 11-K
  Transition Report on Form 10-Q
  Transition Report on Form N-SAR


For the Transition Period Ended: N/A


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  N/A







The registrant is Icagen, Inc. (the “Company”).  The address of the Company’s principal executive office is 4222 Emperor Blvd., Suite 350 Research Triangle Park, Durham, North Carolina 27703.




If the subject report could not be filed without unreasonable effort or expense and the Company seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check appropriate box.)


☒           (a)             The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;


           (b)             The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and


           (c)             The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




The Company is unable to file its Annual Report on Form 10-K for its fiscal year ended December 31, 2016 by the prescribed date without unreasonable effort or expense because the Company was unable to compile and review certain information required in order to permit the Company to file a timely and accurate report on the Company’s financial condition. The Company believes that the Annual Report will be completed and filed within the fifteen day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.




(1)          Name and telephone number of person to contact in regard to this notification:


Mark Korb               (919) 941-5206


(2)          Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Company was required to file such report(s) been filed? If the answer is no, identify report(s).


☒   Yes                     ☐ No


(3)          Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings to be included in the subject report or portion thereof?


Yes                       ☒ No


The Company is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2016 because the Company is still compiling and reviewing information to complete the annual review of the financial statements for that period and the Company is unable to give an estimate at this time. The Company anticipates that the Annual Report on Form 10-K will be filed on or before the deadline. 





Icagen, Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.


  Icagen, Inc.
Dated:  March 31, 2017 By:     /s/ Mark Korb
    Mark Korb
    Chief Financial Officer